E Cavedo, S Lista, Z Khachaturian, P Aisen, P Amouyel, K Herholz, C R Jack, R Sperling, J Cummings, K Blennow, S O'Bryant, G B Frisoni, A Khachaturian, M Kivipelto, W Klunk, K Broich, S Andrieu, M Thiebaut de Schotten, J-F Mangin, A A Lammertsma, K Johnson, S Teipel, A Drzezga, A Bokde, O Colliot, H Bakardjian, H Zetterberg, B Dubois, B Vellas, L S Schneider, H Hampel
Alzheimer's disease (AD) is a slowly progressing non-linear dynamic brain disease in which pathophysiological abnormalities, detectable in vivo by biological markers, precede overt clinical symptoms by many years to decades. Use of these biomarkers for the detection of early and preclinical AD has become of central importance following publication of two international expert working group's revised criteria for the diagnosis of AD dementia, mild cognitive impairment (MCI) due to AD, prodromal AD and preclinical AD...
December 2014: Journal of Prevention of Alzheimer's Disease